Search Results for: Oral melanoma

The COP evaluates novel therapies in pet dogs with cancer to improve outcomes for human patients and established the Comparative Oncology Trial Consortium (COTC), a collaborative effort of NCI and extramural comparative oncology centers at 19 Read More...

The Biopharmaceutical Development Program (BDP) provides resources for the development of investigational biological agents. The BDP supports feasibility through development and Phase I/II cGMP manufacturing plus regulatory documentation. BDP is a DCTD-dedicated facility, but Read More...

Mutation Detection:: For PCR and Sanger sequencing both testing and bioinformatics interpretation are conducted. This method is currently being used in patients with chronic granulomatous disease (CGD), WHIM syndrome, and other autoimmune disorders. Because Sanger Read More...

The Center for Advanced Preclinical Research (CAPR) specializes in evaluating the efficacy of preclinical compounds, existing drugs, or biologics (therapeutics) in genetically engineered mouse (GEM) models, GEM-derived allograft (GDA) models, or patient-derived mouse xenografts (PDX). Read More...

The National Cancer Institute (NCI) is developing a national repository of Patient-Derived Models (PDMs) comprised of patient-derived xenografts (PDXs), in vitro patient-derived tumor cell cultures (PDCs) and cancer associated fibroblasts (CAFs) as well as patient-derived Read More...

CREx Monthly Newsletter Learn about the NIH Collaborative Research Exchange (CREx), Core Facilities, Webinars, & More New Resources on CREx NIH NeuroBioBank (NBB) The NBB provides researchers with access to human post-mortem brain tissue Read More...